Skip to content

ImmunityBio, Inc. IBRX Payments to Acquire Other Investments

Payments to Acquire Other Investments at other companies

Gilead Sciences logo
Gilead SciencesGILD
Eli Lilly logo
Eli LillyLLY
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireOtherInvestments.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s payments to acquire other investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s payments to acquire other investments?
ImmunityBio, Inc. (IBRX) reported payments to acquire other investments of $10M in Q1 2026.